In a new thesis, Mattias Hammarström studied whether lower doses of tamoxifen and also its active metabolite endoxifen for direct administration, as a preventive medication could reduce side effects while still affecting breast tissue in healthy women. The findings suggest that lower doses of tamoxifen and a low dose of endoxifen may offer a better balance between biological effects and side effects, potentially contributing to more individualized approaches to breast cancer prevention.